



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

EV Reporting process for users: Export functions in EVWEB

Training Module EV-M3c






Content Summary

- Introduction
- Implementation of the Access Policy in EVWEB
- ICSR Export – L2A/L2B (Pharmacovigilance obligations)
- ICSR Export MLM service
- Export previously sent ICSRs
- Summary

Content Summary



- Introduction
- Implementation of the Access Policy in EVWEB
- ICSR Export – L2A/L2B (Pharmacovigilance obligations)
- ICSR Export MLM service
- Export previously sent ICSRs
- Summary



Introduction: Target audience

- Target audience for this training module:
 - National Competent Authorities (NCAs) in the European Economic Area (EEA)
 - Marketing authorisation holders (MAHs)
 - Sponsors of clinical trials (Sponsors)
 - Research institutions/Academia

Introduction: Learning objectives

Following the completion of EV-M3c training module you should be able to understand:

- Implementation of the Access Policy in EVWEB
- ICSR Export – L2A/L2B (Pharmacovigilance obligations)
- ICSR Export - MLM service
- Export previously sent ICSRs

Implementation of the Access Policy in EVWEB


- **National Competent Authorities**
 - Full Access to all data held in EudraVigilance (L3)
- **Marketing Authorisation Holders**
 - Full Access to all data sent by their organisation (Sender based L3)
 - Partially restricted access to ICSRs sent by other organisations where they concern suspect drugs for which they hold Marketing Authorisation. This product must be entered and validated in XEVMPD in order for the access to be granted (Pharmacovigilance obligations – Level L2A & L2B)
 - All other ICSRs that do not fit in the above two categories will have restricted access (L1)
 - No Access to Clinical Trial data apart from sender based



Implementation of the Access Policy in EVWEB

- **Sponsors of clinical trials**
 - Full Access to all data sent by their organisation (Sender based L3)
 - All other ICSRs will have restricted public access (L1)

Pharmacovigilance obligations access - Level L2A & L2B





Pharmacovigilance obligations access - Level L2A & L2B

- The EudraVigilance system updates the list of MAHs that are permitted L2A/L2B access for every ICSR in the database, this is carried out each night.
- MAHs do not need to set filters for substance or products names to perform the Export of ICSRs. Only the dates for extraction need to be set.
- Dates for extraction are based on the date of recoding any suspect drug substance or product names within an ICSR against Art57/XEVMPD



Summary

- Implementation of the Access Policy in EudraVigilance
- ICSR Export – L2A/L2B (Pharmacovigilance obligations)
- ICSR Export - MLM service
- Export previously sent ICSRs



Feedback

- Please provide us with feedback on this E-learning module and any attendant guidance documents you have viewed by taking the EMA training survey.
- The survey is accessible via [this link](#).

Save a backup on your local computer (disable if you are using a public/shared computer)

EudraVigilance training feedback survey

Fields marked with * are mandatory.

Disclaimer

The European Commission is not responsible for the content of questionnaires created using the EUSurvey service - it remains the sole responsibility of the form creator and manager. The use of EUSurvey service does not imply a recommendation or endorsement, by the European Commission, of the views expressed within them.

Pages [Training Details](#) [Training Feedback](#)

Training Details

EUROPEAN MEDICINES AGENCY
SCIENCE. MEDICINES. HEALTH.

Views
Standard [Accessibility Mode](#)

Languages
[EN] English ▾

Useful links
[EudraVigilance training page](#)

Contact
[European Medicines Agency service desk](#)

[Download PDF version](#)



Thank you for your attention

Further information/ **Contact information**

European Medicines Agency

30 Churchill Place • Canary Wharf • London E14 5EU •
United Kingdom

Telephone +44 (0)20 3660 6000 **Facsimile** +44 (0)20 3660
5555

Send a question via our website www.ema.europa.eu/contact

Follow us on  **@EMA_News**

